Hansoh Pharma issues fresh equity to raise HK$3.5bn

By Jonathan Breen
22 Apr 2020

Hansoh Pharmaceutical Group, a China-based drug maker, has pocketed HK$3.49bn ($450m) from a larger-than-planned issue of primary shares.

The company turned to investors on Tuesday to raise capital to fund further research and development into its new and existing drugs, which cover illnesses including cancer, diabetes and other infections.

Placing agents Citi and Morgan Stanley kicked off an accelerated bookbuild for the transaction in the evening ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial